April 6, 2021 5:03pm

Answer: The advance/decline line and sentiment by upside momentum profit-taking

Pre-open indication results: 7 HIT and 2 Miss

The Biostage (BSTG) Chronicles: WHO is running this company, WHAT is the relationship with … LIU Dong-hai of Dixintong Technology Group in China of which Jason Chen is chairman of BSTG and a VP of Dixintong. WHAT is LIU Dong-hai’s relationship with DST Capital in funding the company and managed by Mrs. bin Zhao of Weston, Ma? HOW many times did Shunfu Hu, VP of business development and operations say <to me> that Beijing, China based LIU Dong-hai was the ULTIMATE AUTHORITY in BSTG’s future?

The sector is what it is, until it isn’t and even then, it doesn’t seem to be …

I say today what others won't, so you can do what others can't whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors


The Dow closed DOWN -96.95 points (-0.29%); the S&P closed DOWN -3.97 points (-0.10%) while the Nasdaq closed DOWN -7.21 points (-0.05%)



Indexes fell from record levels on Tuesday as the cell and gene therapy sector’s recent two (2) session rally took a pause.

… It seems to be a normal follow-on movement …

The IBD/TIPP Economic Optimism Index, an early monthly read on consumer confidence, rose one point to 56.4 in April. This comes after it popped 3.5 points in March. Readings above the neutral 50 level reflect optimism. It was the fourth straight monthly gain and the highest reading since early February 2020.

Is there a negative under-current of tax increase to 28% by President Biden and his $2 trillion infrastructure proposal announced last week and its chance to become a reality?


RegMed Investors’ (RMi) pre-open: “what’s normal in this market?” … https://www.regmedinvestors.com/articles/11849


Pre-open indication results:  7 HITs <Maintain SELL: Biostage (BSTG -$0.05 to $1.25 with 2,008 – more “pumping” to prevent share price dropping further): SELL into Strength: Alnylam Pharmaceuticals (ALNY -$0.64), Intellia Therapeutics (NTLA -$0.61), uniQure NV (QURE +$0.06), Vericel (VCEL +$1.27), CRISPR Therapeutics (CRSP -$0.36), Editas Medicine (EDIT -$0.22)> and 2 MISS < Cellectis SA (CLLS -$1.09), Voyager Therapeutics (VYGR -$0.13)>  


RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines: progressions and regressions …

  • Tuesday opened positive at 24/8, 2 flat and 1 acquired, stayed positive at the mid-day to 18/15, 1 flat and 1 acquired, closing negative at 10/24, 1 acquired.


There are clear winners and losers

Jumping with share pricing momentum: yesterday’s dogs get to bark again

  • Vericel (VCEL), Sage Therapeutics (SGMO), ReNeuron (RENE.L), Intellia Therapeutics (NTLA), MiMedx (MDXG) to name 5 of the 10 inclining of the 35 covered

Hammered in today’s market:

  • Ultragenyx (RARE), Fate Therapeutics (FATE), Cellectis SA (CLLS), bluebird bio (BLUE), Sangamo Therapeutics (SGMO) to name 5 of the 24 declining of the 35 covered


Key metrics:

  • Sector volume had LOW with 4 of the 10-upside having higher than the 3-month average volume with the volume of 2 of 24-downside having higher than the 3-month average volume;
  • Tuesday’s percentage (%) of the 10-upside were +0.17% (QURE) to +7.41% (MDXG) while the 24-downside ranges from -0.07% (GBT) to -8.10% (PGEN);


Tuesday’s (10 of 10) incline

  • ReNeuron (RENE.L +$1.50);
  • Sage Therapeutics (SAGE +$1.40 after Monday’s +$1.01);
  • Vericel (VCEL +$1.27 after Monday’s +$1.07);
  • BioLife Solutions (BLFS +$1.09 after Monday’s -$0.97);
  • MiMedx (MDXG +$0.84);
  • Ionis Pharmaceuticals (IONS +$0.41 after Monday’s +$1.79);
  • Mesoblast (MESO +$0.19 after Monday’s -$0.05);
  • Verastem (VSTM +$0.07);
  • uniQure NV (QURE +$0.06 after Monday’s +$1.67);
  • AxoGen (AXGN +$0.06);

Tuesday’s (10 of 24) decliners:

  • Ultragenyx (RARE -$4.23);
  • Fate Therapeutics (FATE -$3.56 after Monday’s -$1.75);
  • Cellectis SA (CLLS -$1.09 after Monday’s +$1.19);
  • bluebird bio (BLUE -$0.94 after Monday’s +$1.06);
  • Sangamo Therapeutics (SGMO -$0.79);
  • Adverum Biotechnologies (ADVM -$0.67);
  • Alnylam Pharmaceuticals (ALNY -$0.64 after Monday’s +$0.84):
  • Precision (PGEN -$0.62 after Monday’s +$0.66);
  • Intellia therapeutics (-$0.61);
  • Chinook Therapeutics (KDNY -$0.44 after Monday’s -$0.23);
  • Homology Medicine (FIXX -$0.33)

Closing: 1 - Stemline Therapeutics (STML – acquired)


Sentiment and COVID-19:

  • White House chief medical advisor Dr. Anthony Fauci said that Americans should continue to receive two (2) doses of the Pfizer (PFE) and Moderna (MRNA) Covid-19 vaccines.
  • A Centers for Disease Control and Prevention study published last week found a single dose of the vaccines was 80% effective in preventing coronavirus infections.

Infection cases <Million>: never to forget …

  • Tuesday vaccinations: 167 M
  • Tuesday 30.53 M cases,
  • Tuesday’s death rate totaled 554,064 <Johns Hopkins University>



The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Tuesday, the IBB closed down -0.39% and XBI closed down -2.62%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Tuesday was up +0.21 points or +1.17% at 18.12

Upside volume: low

  • Tuesday: 4 out of the 10-upside had higher than the 3-month average volume;

Downside volume: low

  • Tuesday: 2 out of the 24-downside had higher than the 3-month average volume;

Percentage (%) movement/range statistics: % and pricing drop

  • Tuesday’s percentage (%) of the 10-upside were +0.17% (QURE) to +7.41% (MDXG) while the 24-downside ranges from -0.07% (GBT) to -8.10% (PGEN);


April, the beginning of Q2/21:

Tuesday closed negative with 10 advancers, 24 decliners and 1 acquired

Monday (4/5) closed positive with 24 advancers, 8 decliners, 2 flat and 1 acquired


The BOTTOM LINE: Investors are here to make money from investments that is WHY, I say SELL into Strength!

I’m STILL a “beware or the cautious man” whose focus has always been “warning analysis” … earnings’ season is NOT over … my advice, trim and skim any new highs if one can!”


Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.